News

search close

Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants

Read more

New Report Initiates Coverage on New Public Biopharmaceutical Company, Relmada Therapeutics, Inc.

Read more

Relmada Therapeutics Appoints Julie J. Chen As Director of Finance and Operations

Read more

Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development

Read more

Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER

Read more

Relmada Announces The Filing Of Clinical Trial Application In Canada For d-methadone

Read more

Relmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company

Read more

Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014

Read more

Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker

Read more